Vernalis
From Wikipedia, the free encyclopedia
| Vernalis plc (LSE:VER.L Nasdaq:VNLS) |
|
|---|---|
| Type | Public |
| Founded | 2003 from merger |
| Headquarters | Winnersh, United Kingdom |
| Key people | CEO Robert Mansfield, 1992-2003 Simon Sturge, 2003- Chair George Kennedy, 2000-2003 Peter Fellner, 2003- |
| Industry | Biotechnology |
| Products | Frovatriptan, Apokyn |
| Employees | 200 |
| Website | Vernalis |
Vernalis Plc is a British based biotech company founded in 2003 by the merger of Vernalis Group with British Biotech in a deal valued at £90 million.[1] The merger allowed British Biotech to ditch its historic but tarnished name.[2]
The company has marketed two drug products; Frovatriptan,,[3] to treat migraine, and Apokyn, an apomorphine-based drug for advanced Parkinson's disease.[4]
The company has a development pipeline focused on CNS disease and oncology, and collaborates with pharmaceutical companies including Novartis, Servier, ChemGenex and Serono.
[edit] External links
[edit] References
- ^ Vernalis agrees £91m merger plan with British Biotech. Advances in Life Science. ALS (2003). Retrieved on 2003-07-03.
- ^ Fifth Report. Select Committee on Science and Technology. House of Commons (1998). Retrieved on 2007-11-28.
- ^ Patient Information Sheet -- Frovatriptan succinate (marketed as Frova). Food and Drug Administration (07/2006). Retrieved on 2007-11-28.
- ^ Apokyn. FDA (2004). Retrieved on 2004-07-29.
 |
This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help Wikipedia by expanding it. |
